ACHL NASDAQ
Achilles Therapeutics plc
1W: +2.8%
1M: +7.2%
3M: +53.4%
1Y: +14.7%
3Y: -52.9%
$1.48
Last traded 2025-03-24 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
#657
of 1064
Biotechnology
Technical Signal Map
3 Bullish
1 Neutral
9 Bearish
ACHL
$60M
Achilles Therapeutics plc
N/A
0
OXB.L
$620M
Oxford Biomedica plc
BULLISH
+87
4BB.L
$100M
4basebio PLC
BULLISH
+78
ONT.L
$2.8B
Oxford Nanopore Technologies plc
BULLISH
+66
AVCT.L
$440M
Avacta Group Plc
LEAN BEAR
-25
GNS.L
$1.9B
Genus plc
BEARISH
-56
ROIV
$26B
Roivant Sciences Ltd.
BEARISH
-68
SLN
$570M
Silence Therapeutics plc
BEARISH
-78
CMPS
$1.6B
COMPASS Pathways plc
BEARISH
-84
IMCR
$1.6B
Immunocore Holdings plc
BEARISH
-84
AUTL
$490M
Autolus Therapeutics plc
BEARISH
-84
SCLP.L
$150M
Scancell Holdings plc
BEARISH
-91
BCYC
$250M
Bicycle Therapeutics plc
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| ACHL Achilles Therapeutics plc | $60M | -0.9 | -44.3 | -225.5 | — | — | 2 | N/A | 14.7 |
| OXB.L Oxford Biomedica plc | $620M | -15.7 | -125.1 | -34.2 | -46.3 | 51.0 | 4 | BULLISH | -2.3 |
| 4BB.L 4basebio PLC | $100M | -4.8 | 1643.5 | -279.6 | -3406.1 | 169.5 | 4 | BULLISH | -36.4 |
| ONT.L Oxford Nanopore Technologies plc | $2.8B | -14.0 | -52.8 | -79.1 | -41.1 | 33.2 | 3 | BULLISH | 14.3 |
| AVCT.L Avacta Group Plc | $440M | -7.9 | -546.4 | -1414.8 | -33969.6 | -65.3 | 2 | LEAN BEAR | 48.5 |
| GNS.L Genus plc | $1.9B | 5.0 | 46.3 | 14.0 | 79.2 | -2.0 | 5 | BEARISH | -18.1 |
| ROIV Roivant Sciences Ltd. | $26B | -94.0 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BEARISH | 126.8 |
| SLN Silence Therapeutics plc | $570M | -2.8 | -90.4 | 157.8 | — | -97.6 | 1 | BEARISH | 108.6 |
| CMPS COMPASS Pathways plc | $1.6B | -2.1 | -319.1 | 48.8 | — | — | 2 | BEARISH | 106.2 |
| IMCR Immunocore Holdings plc | $1.6B | -164.8 | -2.3 | -472.0 | -0.7 | 13.4 | 4 | BEARISH | -17.3 |
| AUTL Autolus Therapeutics plc | $490M | -1.7 | -132.9 | 451.5 | -85.6 | 292.0 | 3 | BEARISH | 6.6 |
| SCLP.L Scancell Holdings plc | $150M | -17.9 | 211.7 | 3519.8 | — | -10.6 | 1 | BEARISH | -9.5 |
| BCYC Bicycle Therapeutics plc | $250M | -1.2 | -32.3 | -1197.0 | -8002.1 | 217.4 | 4 | BEARISH | -59.4 |
| ACHL Achilles Therapeutics plc | $60M | -0.9 | -44.3 | -225.5 | — | — | 2 | N/A | 14.7 |
| OXB.L Oxford Biomedica plc | $620M | -15.7 | -125.1 | -34.2 | -46.3 | 51.0 | 4 | BULLISH | -2.3 |
| 4BB.L 4basebio PLC | $100M | -4.8 | 1643.5 | -279.6 | -3406.1 | 169.5 | 4 | BULLISH | -36.4 |
| ONT.L Oxford Nanopore Technologies plc | $2.8B | -14.0 | -52.8 | -79.1 | -41.1 | 33.2 | 3 | BULLISH | 14.3 |
| AVCT.L Avacta Group Plc | $440M | -7.9 | -546.4 | -1414.8 | -33969.6 | -65.3 | 2 | LEAN BEAR | 48.5 |
| GNS.L Genus plc | $1.9B | 5.0 | 46.3 | 14.0 | 79.2 | -2.0 | 5 | BEARISH | -18.1 |
| ROIV Roivant Sciences Ltd. | $26B | -94.0 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BEARISH | 126.8 |
| SLN Silence Therapeutics plc | $570M | -2.8 | -90.4 | 157.8 | — | -97.6 | 1 | BEARISH | 108.6 |
| CMPS COMPASS Pathways plc | $1.6B | -2.1 | -319.1 | 48.8 | — | — | 2 | BEARISH | 106.2 |
| IMCR Immunocore Holdings plc | $1.6B | -164.8 | -2.3 | -472.0 | -0.7 | 13.4 | 4 | BEARISH | -17.3 |
| AUTL Autolus Therapeutics plc | $490M | -1.7 | -132.9 | 451.5 | -85.6 | 292.0 | 3 | BEARISH | 6.6 |
| SCLP.L Scancell Holdings plc | $150M | -17.9 | 211.7 | 3519.8 | — | -10.6 | 1 | BEARISH | -9.5 |
| BCYC Bicycle Therapeutics plc | $250M | -1.2 | -32.3 | -1197.0 | -8002.1 | 217.4 | 4 | BEARISH | -59.4 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
ACHL vs Benchmarks
ROIC
P/E Ratio
ROE
Piotroski F